Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Megan Houweling"'
Autor:
Dieter Henrik Heiland, Bart A. Westerman, Thomas Wurdinger, Megan Houweling, Hamza Saleem, Monika E. Hegi, Fleur M.G. Cornelissen, U. Kulsoom Abdul, Asli Küçükosmanoglu, David Bailey, Mathilde C.M. Kouwenhoven
Publikováno v:
Drug Resistance Updates, 43, 29-37. Churchill Livingstone
Saleem, H, Kulsoom Abdul, U, Küçükosmanoglu, A, Houweling, M, Cornelissen, F M G, Heiland, D H, Hegi, M E, Kouwenhoven, M C M, Bailey, D, Würdinger, T & Westerman, B A 2019, ' The TICking clock of EGFR therapy resistance in glioblastoma : Target Independence or target Compensation ', Drug Resistance Updates, vol. 43, pp. 29-37 . https://doi.org/10.1016/j.drup.2019.04.002
Drug resistance updates, 43, 29-37. Churchill Livingstone
Saleem, H, Kulsoom Abdul, U, Küçükosmanoglu, A, Houweling, M, Cornelissen, F M G, Heiland, D H, Hegi, M E, Kouwenhoven, M C M, Bailey, D, Würdinger, T & Westerman, B A 2019, ' The TICking clock of EGFR therapy resistance in glioblastoma : Target Independence or target Compensation ', Drug Resistance Updates, vol. 43, pp. 29-37 . https://doi.org/10.1016/j.drup.2019.04.002
Drug resistance updates, 43, 29-37. Churchill Livingstone
Targeted therapy against driver mutations responsible for cancer progression has been shown to be effective in many tumor types. For glioblastoma (GBM), the epidermal growth factor receptor (EGFR) gene is the most frequently mutated oncogenic driver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2456e553caa48d8a4a8789a25c092d47
https://doi.org/10.1016/j.drup.2019.04.002
https://doi.org/10.1016/j.drup.2019.04.002
Autor:
Jan B. Koenderink, Jeroen J. M. W. van den Heuvel, Karl M. Weigand, Megan Houweling, Anita C A Dankers, Rick Greupink, Frans G. M. Russel, Tom J.J. Schirris
Publikováno v:
Toxicology in Vitro, 56, pp. 52-61
Toxicology in Vitro, 56, 52-61
Toxicology in Vitro, 56, 52-61
Chronic kidney disease (CKD) is accompanied by accumulating levels of uremic solutes in the circulation. Changes in the size and composition of the bile acid pool have also been observed. We investigated via which mechanisms uremic solutes may interf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::357d8d184673ba1724df7e47bda1854e
https://hdl.handle.net/2066/202078
https://hdl.handle.net/2066/202078
Autor:
Ravi S. Narayan, Asli Küçükosmanoglu, Emmanouil Metzakopian, Fleur M.G. Cornelissen, Kulsoom U. Abdul, Megan Houweling, Fredrik Svensson, David Bailey, Thomas Wurdinger, Bart A. Westerman, Colin Watts
Publikováno v:
Drug Resistance Updates, 40, 17-24. Churchill Livingstone
Drug resistance updates, 40, 17-24. Churchill Livingstone
Abdul, K U, Houweling, M, Svensson, F, Narayan, R S, Cornelissen, F M G, Küçükosmanoglu, A, Metzakopian, E, Watts, C, Bailey, D, Wurdinger, T & Westerman, B A 2018, ' WINDOW consortium : A path towards increased therapy efficacy against glioblastoma ', Drug Resistance Updates, vol. 40, pp. 17-24 . https://doi.org/10.1016/j.drup.2018.10.001
Drug resistance updates, 40, 17-24. Churchill Livingstone
Abdul, K U, Houweling, M, Svensson, F, Narayan, R S, Cornelissen, F M G, Küçükosmanoglu, A, Metzakopian, E, Watts, C, Bailey, D, Wurdinger, T & Westerman, B A 2018, ' WINDOW consortium : A path towards increased therapy efficacy against glioblastoma ', Drug Resistance Updates, vol. 40, pp. 17-24 . https://doi.org/10.1016/j.drup.2018.10.001
Glioblastoma is the most common and malignant form of brain cancer, for which the standard treatment is maximal surgical resection, radiotherapy and chemotherapy. Despite these interventions, mean overall survival remains less than 15 months, during
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e376889b005c294a3ec77aa0e26b94f1
https://research.vumc.nl/en/publications/446f553b-241c-4656-9316-4dbf455b9873
https://research.vumc.nl/en/publications/446f553b-241c-4656-9316-4dbf455b9873